Clinical trial
Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung…
NCT00010218 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00010218 |
|---|---|
| Title | Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer |
| Official title | Phase II Trial Of Karenitecin (IND 57250) In Patients With Relapsed or Refractory Non-small Cell Lung Cancer |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | karenitecin |
| Enrollment | 55 |
| Start date | Apr 1, 2001 |
| Primary completion | Apr 1, 2003 |
| Completion | Jan 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 19, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: